Novo Nordisk built its last five years on a single, compounding bet: that its GLP-1 franchise — Ozempic, Wegovy — was just the opening act. CagriSema, a novel combination of semaglutide with cagrilintide (a long-acting amylin analogue), was scripted as the leapfrog. On February 23, 2026, that script collapsed.
In the REDEFINE 4 Phase 3 trial — an 84-week, open-label, head-to-head study of 809 obese adults — CagriSema 2.4/2.4 mg produced 23.0% body-weight reduction. Eli Lilly's tirzepatide 15 mg produced 25.5%. CagriSema failed its primary endpoint of non-inferiority. Copenhagen-listed shares fell more than 15% intraday, erasing most of the gains accumulated during the Wegovy boom. Lilly rose 3–4%.
The Number Inside the Number
The headline gap of 2.5 percentage points is damaging. The number that should concern investors more is 3.4 points.
Novo reported two estimands. The efficacy estimand — weight loss assuming full treatment adherence — showed 23.0% versus 25.5%. The treatment-regimen estimand — capturing real-world-like outcomes regardless of adherence — showed 20.2% versus 23.6%. The gap widens when patients actually behave like patients.
This divergence is commercially decisive. Obesity drugs are not won on peak trial efficacy alone. They are won on persistence through titration, physician confidence, and payer-negotiated formulary position. A widening treatment-regimen gap implies CagriSema may face greater adherence friction in practice — a problem that no label claim can fully paper over.
What the Open-Label Design Tells Us
REDEFINE 4 was open-label: investigators and participants knew which drug they received. For an objective endpoint like body weight, this is less distorting than symptom-driven outcomes — but it still contaminates discontinuation behavior, AE reporting intensity, and investigator management. Paradoxically, the treatment-regimen estimand — precisely the measure most affected by such behavioral dynamics — is the one showing the largest competitive gap. That is not reassuring.
Novo's Pipeline Math, Reassessed
Novo's FDA submission for CagriSema was filed in December 2025, based on the placebo-controlled REDEFINE 1 and REDEFINE 2 pivotal trials, not REDEFINE 4. An FDA decision is anticipated by late 2026. Approval remains plausible. But a drug can be approved and commercially diminished simultaneously.
Novo's response to REDEFINE 4 is a higher-dose Phase 3 trial of CagriSema 2.4/7.2 mg, planned to initiate in the second half of 2026, with REDEFINE 11 readout expected in the first half of 2027. The logic is scientifically coherent: the amylin component may simply be underdosed at the fixed 2.4/2.4 ratio. But the execution risk is real — higher cagrilintide exposure could worsen GI tolerability, drive discontinuations, and reproduce the adherence gap at a larger scale. The question is not whether higher doses produce more weight loss. It is whether they produce more net weight loss on a treatment-regimen estimand with sustainable persistence.
The Repricing Is a Process, Not an Event
Novo's stock trades at approximately 12.7x forward earnings following today's selloff — a valuation that signals the market has reset growth expectations, not merely discounted a single data point. That compression is warranted, but investors buying the dip should understand what they are actually buying.
The next decisive catalysts — REDEFINE 11 data, high-dose trial initiation, FDA decision — are distributed across late 2026 and into 2027. In the interim, Lilly holds a clean, head-to-head-validated narrative that payers, physicians, and formulary committees will now use as their reference point. Novo's commercial thesis has shifted from offense to defense: not "CagriSema takes the lead" but "CagriSema earns a segment."
The Verdict
CagriSema is not a failed molecule. A 23% mean weight reduction is clinically substantial. But in a market that rewards a simple, repeatable message — which drug gets more weight loss, reliably — Novo just lost the argument at the doses that matter today. The fix requires time, tolerability management, and at least one more large trial. Meanwhile, Lilly's moat just got measurably wider. For Novo, this is not a setback to a trial. It is a repricing of a thesis.
not investment advice